<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">79940</article-id><article-id pub-id-type="doi">10.7554/eLife.79940</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-278488"><name><surname>Park</surname><given-names>Hae J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7768-9297</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279139"><name><surname>Gregory</surname><given-names>Mark A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279140"><name><surname>Zaberezhnyy</surname><given-names>Vadym</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279141"><name><surname>Goodspeed</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279142"><name><surname>Jordan</surname><given-names>Craig T</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-207430"><name><surname>Kieft</surname><given-names>Jeffrey S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-184975"><name><surname>DeGregori</surname><given-names>James</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1287-1976</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Biochemistry and Molecular Genetics</institution>, <institution>University of Colorado Anschutz Medical Campus</institution>, <addr-line><named-content content-type="city">Aurora</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Pharmacology</institution>, <institution>University of Colorado Anschutz Medical Campus</institution>, <addr-line><named-content content-type="city">Aurora</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Medicine</institution>, <institution>University of Colorado Anschutz Medical Campus</institution>, <addr-line><named-content content-type="city">Aurora</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-265348"><name><surname>Henske</surname><given-names>Elizabeth P</given-names></name><role>Reviewing editor</role><aff><institution>Brigham And Women's Hospital</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>James.Degregori@cuanschutz.edu</email> (JD);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>10</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e79940</elocation-id><history><date date-type="received"><day>03</day><month>05</month><year>2022</year></date><date date-type="accepted"><day>17</day><month>10</month><year>2022</year></date></history><permissions><copyright-statement>Â© 2022, Park et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Park et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-79940-v1.pdf"/><abstract><p>While leukemic cells are susceptible to various therapeutic insults, residence in the bone marrow microenvironment typically confers protection from a wide range of drugs. Thus, understanding the unique molecular changes elicited by the marrow is of critical importance towards improving therapeutic outcomes. In the present study, we demonstrate that aberrant activation of oxidative phosphorylation serves to induce therapeutic resistance in FLT3 mutant human AML cells challenged with FLT3 inhibitor drugs. Importantly, our findings show that AML cells are protected from apoptosis following FLT3 inhibition due to marrow-mediated activation of ATM, which in turn up-regulates oxidative phosphorylation via mTOR signaling. mTOR is required for the bone marrow stroma-dependent maintenance of protein translation, with selective polysome enrichment of oxidative phosphorylation transcripts, despite FLT3 inhibition. To investigate the therapeutic significance of this finding, we tested the mTOR inhibitor everolimus in combination with the FLT3 inhibitor quizartinib in primary human AML xenograft models. While marrow resident AML cells were highly resistant to quizartinib alone, the addition of everolimus induced profound reduction in tumor burden and prevented relapse. Taken together, these data provide a novel mechanistic understanding of marrow-based therapeutic resistance, and a promising strategy for improved treatment of FLT3 mutant AML patients.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>Graduate Student Fellowship,NRSA F30CA23197</award-id><principal-award-recipient><name><surname>Park</surname><given-names>Hae J</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R35GM118070</award-id><principal-award-recipient><name><surname>Kieft</surname><given-names>Jeffrey S</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001368</institution-id><institution>V Foundation for Cancer Research</institution></institution-wrap></funding-source><award-id>T2016-012</award-id><principal-award-recipient><name><surname>DeGregori</surname><given-names>James</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006058</institution-id><institution>St. Baldrick's Foundation</institution></institution-wrap></funding-source><award-id>AWD-430131</award-id><principal-award-recipient><name><surname>DeGregori</surname><given-names>James</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005189</institution-id><institution>Leukemia and Lymphoma Society</institution></institution-wrap></funding-source><award-id>7020-19</award-id><principal-award-recipient><name><surname>Jordan</surname><given-names>Craig T</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005189</institution-id><institution>Leukemia and Lymphoma Society</institution></institution-wrap></funding-source><award-id>7020-19</award-id><principal-award-recipient><name><surname>DeGregori</surname><given-names>James</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experiments were approved by and performed in accordance with guidelines of the Institutional Animal Care and Use Committee at University of Colorado (protocol No. 00170).</p></fn><fn fn-type="other"><p>Human subjects: Deidentified primary AML studies were obtained with donor consent from patients at the University of Colorado Anschutz Medical Campus (COMIRB protocol #12-0173)</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in manuscript and supporting file. RNA-seq data have been deposited in GEO under accession codes GSE202230.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Park H et al</collab></person-group><year iso-8601-date="2022">2022</year><source>Investigation of bone marrow mediated therapeutic resistance to FLT3 inhibition in acute myeloid leukemia cells</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE202230">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE202230</ext-link><comment>NCBI Gene Expression Omnibus, GSE202230</comment></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Jiang D</collab><collab>Zhang Y</collab><collab>Hart RP</collab><collab>Chen J et al</collab></person-group><year iso-8601-date="2015">2015</year><source>Ataxia-telangiectasia cerebellar cortex expression</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61019">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61019</ext-link><comment>NCBI Gene Expression Omnibus,GSE61019</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-79940-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>